DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued on Monday. The firm set a “hold” rating on the stock.

Other equities research analysts have also recently issued reports about the company. HC Wainwright lifted their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research note on Tuesday, December 10th.

DBV Technologies Trading Down 0.3 %

Shares of DBVT stock opened at $3.21 on Monday. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $10.70. The stock’s 50-day moving average price is $3.45 and its 200-day moving average price is $3.96. The stock has a market capitalization of $66.03 million, a price-to-earnings ratio of -0.71 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.